79 related articles for article (PubMed ID: 24860907)
1. Warning: dangers of insulin at 200 units per ml.
Prescrire Int; 2014 Apr; 23(148):111. PubMed ID: 24860907
[No Abstract] [Full Text] [Related]
2. European Medicines Agency must take account of cardiovascular harm associated with degludec insulin.
Schmidt TA; Rosen CJ; Yudkin JS
BMJ; 2013 Jun; 346():f3731. PubMed ID: 23757746
[No Abstract] [Full Text] [Related]
3. FDA raises concerns about ultra-long acting insulins given green light in Europe and Japan.
Torjesen I
BMJ; 2012 Oct; 345():e7323. PubMed ID: 23112064
[No Abstract] [Full Text] [Related]
4. [Clinical use of long-acting insulin analogs].
Birkeland KI
Tidsskr Nor Laegeforen; 2006 Apr; 126(8):1067-8. PubMed ID: 16619068
[No Abstract] [Full Text] [Related]
5. Insulin glargine in children aged 2 to 5 years.
Prescrire Int; 2013 Mar; 22(136):69. PubMed ID: 23593690
[TBL] [Abstract][Full Text] [Related]
6. Acute hepatic injury following treatment of a long-acting insulin analogue overdose necessitating urgent insulin depot excision.
Warriner D; Debono M; Gandhi RA; Chong E; Creagh F
Diabet Med; 2012 Feb; 29(2):232-5. PubMed ID: 21781150
[TBL] [Abstract][Full Text] [Related]
7. Assessing the cardiovascular safety of diabetes therapies.
Goldfine AB
N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
[No Abstract] [Full Text] [Related]
8. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
9. ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
Lombard L; Distiller L; Aalbers J
Cardiovasc J Afr; 2012 Jul; 23(6):357-8. PubMed ID: 23091824
[No Abstract] [Full Text] [Related]
10. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
[TBL] [Abstract][Full Text] [Related]
11. [Hypersensitization to protamine-containing insulin].
Räsänen L; Tuomi ML; Lahtela J; Knip M
Duodecim; 1995; 111(10):914-8. PubMed ID: 9081826
[No Abstract] [Full Text] [Related]
12. Insulin degludec for diabetes mellitus.
Drug Ther Bull; 2013 Jul; 51(7):78-81. PubMed ID: 23842634
[TBL] [Abstract][Full Text] [Related]
13. Lantus? Or Lente?
Berkowitz K
Am J Nurs; 2002 Aug; 102(8):55. PubMed ID: 12394040
[No Abstract] [Full Text] [Related]
14. Insulin glargine use and short-term incidence of breast cancer - a four-year population-based observation.
Ljung R; Talbäck M; Haglund B; Jonasson JM; Gudbjörnsdòttir S; Steineck G
Acta Oncol; 2012 Mar; 51(3):400-2. PubMed ID: 22497435
[No Abstract] [Full Text] [Related]
15. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
[TBL] [Abstract][Full Text] [Related]
16. Integrating advances in insulin into clinical practice: Advances In insulin formulations.
King A
J Fam Pract; 2013 Sep; 62(9 Suppl Insulin):S9-17. PubMed ID: 24080573
[TBL] [Abstract][Full Text] [Related]
17. After Avandia, some seek split in drug approval and monitoring.
Dolgin E
Nat Med; 2010 Aug; 16(8):831. PubMed ID: 20689527
[No Abstract] [Full Text] [Related]
18. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
19. Converting continuous insulin infusion to subcutaneous insulin glargine after cardiac surgery using percentage-based versus weight-based dosing: a pilot trial.
Silinskie KM; Kirshner R; Hite MS
Ann Pharmacother; 2013 Jan; 47(1):20-8. PubMed ID: 23324510
[TBL] [Abstract][Full Text] [Related]
20. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
[Next] [New Search]
